RxDoctor Payments Data

Charles Daniels, MD

Interventional Pain Medicine · Wilmington, NCNPI 1710167168

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Abbott at 54.5% of the total. Reporting peaked in 2023 at $693 and has fallen 59.2% since, to $283 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in NC, where the typical reported total is $2,787.

$1,800in general payments, 2019–2025

Across 64 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$982
  • Forte Bio-pharma LLC$253
  • Medtronic$152
  • Boston Scientific$125
  • Amgen$55
  • Si-bone, Inc.$51
  • plus $182 from 9 others

What the payments were for

  • Food & beverage$1,800100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,800 in reported general payments places this provider in the 30th percentile of 45 interventional pain medicine providers in North Carolina.

See all interventional pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$166,234
Medicare patients
154
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate13$11,453
Buprenorphine37$7,663
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen179$4,546
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen144$4,431
Oxycodone Hcl158$3,687
Gabapentin150$1,745
Topiramate64$1,400
Pregabalin79$1,216
Tramadol Hcl72$624
Cyclobenzaprine Hcl41$476
Tizanidine Hcl53$410
Morphine Sulfate12$373
Morphine Sulfate ErMorphine Sulfate16$324
Baclofen38$278
Duloxetine Hcl14$183

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →